Equities analysts predict that Axovant Sciences Ltd (NASDAQ:AXON) will report earnings of ($0.35) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Axovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.57). Axovant Sciences reported earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year-over-year growth rate of 35.2%. The company is scheduled to report its next earnings results on Friday, February 8th.
According to Zacks, analysts expect that Axovant Sciences will report full year earnings of ($1.67) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($0.78). For the next year, analysts expect that the company will post earnings of ($1.35) per share, with EPS estimates ranging from ($2.56) to ($0.73). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Axovant Sciences.
Axovant Sciences (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.33).
A number of analysts recently weighed in on AXON shares. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Tuesday, October 9th. BidaskClub upgraded Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 16th. ValuEngine upgraded Axovant Sciences from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Cowen restated a “hold” rating on shares of Axovant Sciences in a report on Thursday, September 20th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Axovant Sciences in a report on Monday, August 13th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. Axovant Sciences currently has an average rating of “Hold” and a consensus price target of $4.56.
NASDAQ AXON opened at $2.08 on Friday. The firm has a market capitalization of $247.82 million, a P/E ratio of -1.01 and a beta of 0.43. Axovant Sciences has a twelve month low of $1.02 and a twelve month high of $6.59. The company has a debt-to-equity ratio of 1.48, a current ratio of 2.34 and a quick ratio of 2.34.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Paloma Partners Management Co acquired a new stake in Axovant Sciences in the second quarter valued at $356,000. Tower Research Capital LLC TRC boosted its position in Axovant Sciences by 1,627.0% during the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 58,541 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Axovant Sciences during the second quarter valued at $338,000. JPMorgan Chase & Co. boosted its position in Axovant Sciences by 2,519.0% during the first quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock valued at $244,000 after acquiring an additional 176,227 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Axovant Sciences by 3.4% during the first quarter. BlackRock Inc. now owns 3,012,515 shares of the biotechnology company’s stock valued at $4,006,000 after acquiring an additional 100,296 shares during the last quarter. Institutional investors and hedge funds own 9.32% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.